the potential to minimize the over-diagnosis associated with PSA testing. In addition, therapies for PCa usually involve either reducing or blocking the production of androgen and most PCa patients receive primary androgen deprivation therapy (ADT). However, nearly all men with metastatic PCa develop resistance to primary ADT, a stage of disease known as metastatic castration-resistant PCa (CRPC), which represents the final stage of PCa, with a median survival of less than 2 years. 2, 5 Various molecular mechanisms account for PCa progression, among which aberrations of the androgen receptor (AR) pathway and activation of the phosphatidylinositol 3-kinase(PI3 K)-AKT-mammalian target of rapamycin (mTOR) signaling are two major reasons. 5, 6 PI3K-AKT-mTOR has been associated with poor clinical outcome, 7 biochemical recurrence after radical prostatectomy, 8 and resistance to radiation and chemotherapy. 9 PI3K-AKT-mTOR signaling could be activated via multiple ways, including PTEN loss, decreased expression of INPP4B, PIK3A activating mutation, and so on. Inhibitors of this pathway have great potential to deliver clinical benefit for PCa patients. 6 Therefore, a better understanding for activation mechanism of PI3K-AKT-mTOR signaling in PCa progression is key for selection of optimal therapies and improvement of patient outcome.
Golgi membrane protein 1 (GOLM1), also named Golgi phosphoprotein 2 (GOLPH2) or Gogi protein 73 (GP73), was identified as a novel biomarker for localized PCa, [10] [11] [12] [13] but its biological function and molecular mechanisms remain poorly understood in PCa progression.
GOLM1 is a 73-kDa type II cis-Golgi-localised transmembrane glycoprotein expressed primarily in cells of epithelial lineage, which was originally cloned from a cDNA library of liver tissues from a patient with adult giant-cell hepatitis. 14 GOLM1 is up-regulated and consistently overexpressed in PCa tissues. 10, 12 Aberrant overexpression of GOLM1 has also been reported to correlate with many other cancers and diseases, such as hepatocellular carcinoma, 15 oesophageal cancer, 16 viral infections, 14 Alzheimer's disease, 17 and Wilson's disease. 18 Although GOLM1 normally localizes to the Golgi, it can be secreted out of cell via exosomes or microvesicles, so it can be detected in urine of PCa patients 10 and serum of hepatocellular carcinoma patients. 15 Therefore, GOLM1 may act as an effective biomarker for these diseases.
Currently, the knowledge on the function of GOLM1 is limited. It was reported that GOLM1 acts as a key oncogene by promoting tumor cell invasion, migration, growth, and metastasis in hepatocellular carcinoma 19, 20 and oesophageal cancer. 16 GOLM1 augments hepatocellular carcinoma invasion through activation of the CREB-MMP-13 signaling pathway. 19 The most recent study revealed that GOLM1
promotes hepatocellular carcinoma growth and metastasis through modulating EGFR/RTK cell-surface recycling. 20 Some studies demonstrated GOLM1 as a novel marker for PCa, 10, 12, 13 but its functional role and molecular mechanism are unclear.
In this study, we further identified that GOLM1 expression is up-regulated in PCa. GOLM1 up-regulation significantly promotes cell proliferation, migration and invasion, and inhibits cell apoptosis in PCa cell lines DU145 and PC3 and their xenograft in nude mice, whereas GOLM1 knockdown in DU145 and CWR22Rv1 does the opposite. Figure 3E ) and control PC3 cells (11.67 ± 0.29% vs 21.83 ± 0.76%, *P < 0.05, Figure 3F ), respectively. To further examine the effects of GOLM1 expression in PCa cells, we used GOLM1-specific small interfering RNAs (siGOLM1#1 and siGOLM1#2) or negative control siRNA (siNC) to silence the endogenous GOLM1 expression in AR negative cell DU145 and AR positive cell CWR22Rv1 cell. Real-time PCR
showed that both siGOLM1#1 and siGOLM1#2 induced significant GOLM1 knockdown when compared with siNC in these two cell lines ( Figures 3G and 3H) . Similarly, GOLM1 down-regulation induced 
| GOLM1 promotes PCa cell migration and invasion
Because migratory and invasive activities are essential for cancer cells in the primary sites to metastasize to distant organs, we next investigated whether GOLM1, as a malignant biomarker, may promote PCa cell migration and invasion. Wound-healing assays showed that GOLM1 overexpression significantly increased migration ability of DU145 (100 ± 6.44% vs 148.46 ± 6.31%, *P < 0.05, Figure 4A ) and PC3 cells (100 ± 22.61% vs 188.42 ± 13.31%, *P < 0.05, Figure 4B ). Transwell assays suggested that GOLM1 overexpression significantly increased invasion ability of DU145 (100 ± 21.45% vs 200.44 ± 21.62%, *P < 0.05, Figure 4C ) and PC3 (100 ± 20.27% vs 170.13 ± 21.33%, *P < 0.05, Figure 4D ). Similarly, GOLM1-silencing also induced potent suppression on both migration and invasion of PCa cells. Wound-healing assays showed that the level of migration was remarkably descended in siGOLM1#1 or siGOLM1#2 transfected cells compared with siNC transfected cells (100 ± 5.40% vs 47.60 ± 3.1% or 38.81 ± 10.45%, *P < 0.05, for DU145, Figure 4E ; 100 ± 18.85% vs 51.10 ± 5.04% or 49.21 ± 3.87%, *P < 0.05, for CWR22Rv1, Figure 4F ). Transwell assays showed that the invasion ability of siGOLM1#1 or siGOLM1#2 transfected cells was diminished compared with siNC transfected cells (100 ± 18.14% vs 60.19 ± 7.57% or 55.56 ± 6.60%, *P < 0.05, for DU145, Figure 4G ; 100 ± 13.27% vs 64.24 ± 9.49% or 51.02 ± 5.58%, *P < 0.05, for CWR22Rv1, Figure 4H ). These results demonstrated that GOLM1 plays an important role in PCa cells migration and invasion.
| GOLM1 inhibits PCa cells apoptosis
Next, we asked whether overexpression of GOLM1 affects cell apoptosis induced by chemo drug. To this end, we treated GOLM1-overexpressing DU145 and PC3 cell with cabazitaxel, 21 a novel chemotherapeutic drug of mCRPC, and then determined cell apoptosis via PI-Annexin V double staining followed by the flow cytometry analysis and Western blot. As shown in Figures 5A and 5B, treatment with 100 nM of cabazitaxel led to increased apoptosis at different extent in DU145 and PC3 cells compared with DMSO treatment, but such cabazitaxel-induced apoptosis were significantly compromised by GOLM1 overexpression (35.47 ± 1.55% vs 24.05 ± 3.08%, *P < 0.05, for DU145, Figure 5A ; 19.56 ± 0.12% vs13.78 ± 1.12%, 14.22 ± 3.29% vs 40.75 ± 2.30% or 65.55 ± 6%, *P < 0.05, for CWR22Rv1, Figure 5F ). These data demonstrated that GOLM1
renders PCa cells resistance to cabazitaxel-induced apoptosis.
| GOLM1 activates PI3K-AKT-mTOR signaling
It has been widely accepted that PI3K-AKT-mTOR signaling is not only closely associated with the PCa progression, 6 but also involved in epithelial-to-mesenchymal transtion (EMT) 22 and cancer stem cell maintenance. 23 The most recent study also reported that GOLM1 drives hepatocellular carcinoma metastasis by interacting with EGFR/RTK and facilitating its downstream signaling, which includes AKT. 20 To verify the relationship between GOLM1 and PI3K-AKT-mTOR signaling, we examined the expression of key components of PI3K-AKT-mTOR signaling pathway by Western blot analysis. It was shown that PI3K (p110), p-AKT (Ser473), and p-mTOR (Ser2448) were significantly up-regulated by GOLM1 overexpression in DU145 and PC3 ( Figure 6A ). In addition, we also investigated the effects of GOLM1-silencing on the PI3K-AKT-mTOR signaling pathway. Strikingly, the expression of PI3K (p110), p-AKT (Ser473), and p-mTOR (Ser2448) were significantly decreased when GOLM1 was knocked down by siGOLM1s in DU145 and CWR22Rv1 ( Figure 6B ). Taken together, these data suggested that GOLM1 could activate PI3K-AKT-mTOR signaling in PCa cell lines. 
| GOLM1 promotes PCa progression through activating PI3K-AKT-mTOR signaling
The above data have suggested that GOLM1 could activate PI3K-AKT-mTOR signaling. To evaluate whether GOLM1 plays oncogenic roles in PCa through activating PI3K-AKT-mTOR signaling, we used PI3K inhibitor BKM120 24 to block PI3K-AKT-mTOR signaling and then observed its effect on GOLM1's oncogenic functions.
Western blot analysis showed that BKM120 can effectively inhibit p-AKT (Ser473) level in a dose-dependent manner ( Figure 8A ). CCK8
assays and transwell assays demonstrated that BKM120 at a concentration of 500nM significantly abrogated GOLM1's effect on proliferation and invasion in DU145 cells ( Figures 8B and 8C ). But PIAnnexin V double stain/flow cytometry analysis showed that although GOLM1-overexpression attenuated cabazitaxel-induced cell apoptosis even in the presence of BKM120, cabazitaxel and BKM120 work in concert to induce cell apoptosis in DU145 cells ( Figure 8D ).
Collectively, these data provided strong evidences that GOLM1
promotes PCa cell proliferation and migration mainly through activating PI3K-AKT-mTOR signaling.
FIGURE 5 GOLM1 inhibits PCa cell apoptosis induced by chemodrug. A and B, The apoptosis of stable DU145 and PC3 cells treated with or without 100 nM cabazitaxelwas determined by PI-AnnexinV staining followed by flow cytometric analysis. C and D, Western blot analysis of apoptosis marker PARP in stable cell lines treated with 50 or 100 nM cabazitaxel. E and F, DU145 and CWR22Rv1 cells transfected with siNC, siGOLM1#1 or siGOLM1#2 were treated with 50 nM cabazitaxel and cell apoptosis was determined by PI-AnnexinV staining followed by flow cytometric analysis. Data were means ± SEM.*P < 0.05
has been identified as a novel biomarker for PCa diagnosis. 10 However, its function and mechanism in PCa remains poorly understood. In this study, we found that GOLM1 was up-regulated in all PCa stages and grades, suggesting that GOLM1 may play a critical role in PCa malignancy. By performing in vitro and in vivo gain-and loss-of-function studies, we further provided evidences that GOLM1 significantly promotes cell proliferation, migration and invasion, and inhibits cell apoptosis induced by chemodrug in PCa cells. Moreover, GOLM1 overexpression accelerates PCa xenograft growth in nude mice. Mechanistically, GOLM1 activates PI3K-AKT-mTOR signaling, while PI3 K inhibitor attenuates oncogenic functions of GOLM1.
In mammalian cells, the Gogi apparatus is a single-copy organelle and polarized in both structure and function, with cis-and trans-side playing different roles. The main functions of Golgi are posttranslational modification and sorting of proteins, which are widely associated with mitosis, apoptosis, migration, and invasion. 25 Deregulation of these processes is known to be linked to cancer initiation and progression. Therefore, elucidation of the regulatory networks of the Golgi apparatus will provide useful information for discovery of therapeutic strategies against cancer progression. GOLM1 is a cisGolgi-localized protein and is overexpressed in PCa tissues. 10, 12 Under physiologic conditions, GOLM1 is mainly localized to epithelial cells of prostatic glands, intestinal glands, lung bronchioles, and biliary epithelial cells. 14 GOLM1 overexpression was identified to be correlated with multiple diseases, including hepatocellular carcinoma, 15 oesophageal cancer, 16 viral infections, 14 Alzheimer's disease, 17 and Wilson's disease. 18 Our data further demonstrated that GOLM1 is closely associated with PCa progression in all stages and grades.
Previous studies indicated GOLM1 as a potential novel biomarker for clinically localized PCa, however, specific functions of GOLM1 in PCa was unclear. The studies of GOLM1 functions were also limited in other cancers. It was reported GOLM1 promotes cell migration and invasion in hepatocellular carcinoma 19 and oesophageal cancer. 16 The latest study revealed that GOLM1 promotes hepatocellular carcinoma growth and metastasis by modulating EGFR/RTK cell-surface recycling. 20 In order to explore the role of GOLM1 in PCa cells, we PI3K-AKT-mTOR is a key oncogenic signaling pathway that has been linked to both tumorigenesis and therapy resistance in PCa and other solid tumors. 6, 26 Activation of this pathway is involved in regulation of various cellular function, including cell survival, growth, proliferation, differentiation, migration, stem cell-like properties, metabolism, and angiogenesis. 22, 23, [27] [28] [29] [30] Currently, agents that block various steps in the PI3K-AKT-mTOR signaling pathway are being investigated as novel therapeutics for advanced PCa. 6 Golgi-mediated protein trafficking is closely correlated with activation of various signaling molecules. Previous study revealed that GOLM1's interaction with the membrane EGFR plays a crucial role in EGFR/RTK recycling/ activation. 20 Notably, PI3K-AKT-mTOR signaling pathway is a most common pathway downstream of RTK. 31 Our data showed that several key components of PI3K-AKT-mTOR signaling pathway were positively regulated by GOLM1 expression in PCa cell lines DU145, PC3 and CWR22Rv1, including PI3K (p110), p-AKT (Ser473), p-mTOR (Ser2448), and p-mTOR (Ser2481). 26 The results suggested GOLM1
could activate PI3K-AKT-mTOR signaling pathway. To investigate whether GOLM1 promotes PCa progression by activating In summary, we demonstrated GOLM1 as a key promoter of PCa.
GOLM1 promotes cell proliferation, migration and invasion, and inhibits cell apoptosis. GOLM1 plays oncogenic functions mainly through activating PI3K-AKT-mTOR signaling pathway. GOLM1 not only becomes a novel biomarker for PCa diagnosis, but also is able to guide individualized treatment. Particularly, agents that block PI3K-AKT-mTOR signaling pathway could be used in PCa patients with GOLM1 up-regulation. 
| Vector construction and lentivirus packaging
The GOLM1 CDS was amplified by PCR using primers: GOLM1-BamH I- were obtained by lentiviral infection and puromycin(1 µg/mL) selection.
| RNA interference
Chemically synthesized siRNA duplexes were obtained from GenePharma (Shanghai, China). Negative control siRNA sequence:
5′-UUCUCCGAACGUGUCACGUTT-3′; siGOLM1#1 sequence: 
| Flow cytometry analysis of apoptosis
Cells were treated with DMSO, 50 nM cabazitaxel, 100 nM cabazitaxel or 50 nM cabazitaxel +500 nM BKM120 for 48 h. The apoptotic cells were evaluated by propidium iodine and Annexin V-FITC staining (BD), and analyzed using FACScan apparatus and GraphPad Prism6 software.
| In vivo tumorigenicity assay
The animal studies were approved by the Animal Ethics Committee of the 
| Statistical analysis
Statistical analyses were performed using SPSS 19.0 software and GraphPad Prism6 software. Data are presented as mean ± SEM. All experiments were performed in triplicate. Independent Student t-test or one-way ANOVA were used to compare the continuous variables between the two groups or more than two groups. P < 0.05 was considered to be statistically significant.
